Beyond Blood Smears: Qualification of Plasmodium 18S rRNA as a Biomarker for Controlled Human Malaria Infections

Abstract. 18S rRNA is a biomarker that provides an alternative to thick blood smears in controlled human malaria infection (CHMI) trials. We reviewed data from CHMI trials at non-endemic sites that used blood smears and Plasmodium 18S rRNA/rDNA biomarker nucleic acid tests (NATs) for time to positivity. We validated a multiplex quantitative reverse transcription–polymerase chain reaction (qRT-PCR) for Plasmodium 18S rRNA, prospectively compared blood smears and qRT-PCR for three trials, and modeled treatment effects at different biomarker-defined parasite densities to assess the impact on infection detection, symptom reduction, and measured intervention efficacy. Literature review demonstrated accelerated NAT-based infection detection compared with blood smears (mean acceleration: 3.2–3.6 days). For prospectively tested trials, the validated Plasmodium 18S rRNA qRT-PCR positivity was earlier (7.6 days; 95% CI: 7.1–8.1 days) than blood smears (11.0 days; 95% CI: 10.3–11.8 days) and significantly preceded the onset of grade 2 malaria-related symptoms (12.2 days; 95% CI: 10.6–13.3 days). Discrepant analysis showed that the risk of a blood smear–positive, biomarker-negative result was negligible. Data modeling predicted that treatment triggered by specific biomarker-defined thresholds can differentiate complete, partial, and non-protective outcomes and eliminate many grade 2 and most grade 3 malaria-related symptoms post-CHMI. Plasmodium 18S rRNA is a sensitive and specific biomarker that can justifiably replace blood smears for infection detection in CHMI trials in non-endemic settings. This study led to biomarker qualification through the U.S. Food and Drug Administration for use in CHMI studies at non-endemic sites, which will facilitate biomarker use for the qualified context of use in drug and vaccine trials.

[1]  Center for Devices and Radiological Health , 2020, Definitions.

[2]  M. Levine,et al.  The Controlled Human Malaria Infection Experience at the University of Maryland. , 2019, The American journal of tropical medicine and hygiene.

[3]  P. V. van Genderen,et al.  Controlled Human Malaria Infection with Graded Numbers of Plasmodium falciparum NF135.C10- or NF166.C8-Infected Mosquitoes , 2018, The American journal of tropical medicine and hygiene.

[4]  J. Kublin,et al.  A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation , 2018, The Journal of infectious diseases.

[5]  S. Hoffman,et al.  Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon , 2017, The American journal of tropical medicine and hygiene.

[6]  Chris Leptak,et al.  What evidence do we need for biomarker qualification? , 2017, Science Translational Medicine.

[7]  S. Hoffman,et al.  DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection , 2017, The Lancet. Infectious diseases.

[8]  A. Seilie,et al.  Detection of Babesia microti parasites by highly sensitive 18S rRNA reverse transcription PCR. , 2017, Diagnostic microbiology and infectious disease.

[9]  Mario Roederer,et al.  Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection , 2017, Proceedings of the National Academy of Sciences.

[10]  Sumana Chakravarty,et al.  Sterile protection against human malaria by chemoattenuated PfSPZ vaccine , 2017, Nature.

[11]  Luc E. Coffeng,et al.  The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection , 2017, PLoS Comput. Biol..

[12]  Mario Roederer,et al.  Protection against malaria at 1 year and immune correlates following PfSPZ vaccination , 2016, Nature Medicine.

[13]  D. A. Korevaar,et al.  Molecular malaria diagnostics: A systematic review and meta-analysis* , 2016, Critical reviews in clinical laboratory sciences.

[14]  S. Hoffman,et al.  Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers under Chloroquine Prophylaxis: A Randomized Controlled Trial , 2016, The American journal of tropical medicine and hygiene.

[15]  F. Huang,et al.  An ultrasensitive reverse transcription polymerase chain reaction assay to detect asymptomatic low-density Plasmodium falciparum and Plasmodium vivax infections in small volume blood samples , 2015, Malaria Journal.

[16]  Susan McCune,et al.  Building a roadmap to biomarker qualification: challenges and opportunities. , 2015, Biomarkers in medicine.

[17]  S. Hoffman,et al.  Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates , 2015, Malaria Journal.

[18]  S. Amur,et al.  Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization , 2015, Clinical pharmacology and therapeutics.

[19]  G. van Gemert,et al.  Heterologous Protection against Malaria after Immunization with Plasmodium falciparum Sporozoites , 2015, PloS one.

[20]  S. Hoffman,et al.  Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres , 2015, Malaria Journal.

[21]  S. Hoffman,et al.  Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies , 2015, Malaria Journal.

[22]  J. Kublin,et al.  Safety and Comparability of Controlled Human Plasmodium falciparum Infection by Mosquito Bite in Malaria-Naïve Subjects at a New Facility for Sporozoite Challenge , 2014, PloS one.

[23]  S. Hoffman,et al.  Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection , 2014, Front. Microbiol..

[24]  R. Cortese,et al.  Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals , 2014, The Journal of infectious diseases.

[25]  C. Ockenhouse,et al.  Measurement of parasitological data by quantitative real-time PCR from controlled human malaria infection trials at the Walter Reed Army Institute of Research , 2014, Malaria Journal.

[26]  Andrea A. Berry,et al.  External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance , 2014, PloS one.

[27]  V. A. Stewart,et al.  Malaria diagnostics in clinical trials. , 2013, The American journal of tropical medicine and hygiene.

[28]  Mario Roederer,et al.  Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine , 2013, Science.

[29]  S. Hoffman,et al.  Successful Human Infection with P. falciparum Using Three Aseptic Anopheles stephensi Mosquitoes: A New Model for Controlled Human Malaria Infection , 2013, PloS one.

[30]  D. Carucci,et al.  DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity , 2013, PloS one.

[31]  S. Hoffman,et al.  Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved Plasmodium falciparum Sporozoites , 2013, The American journal of tropical medicine and hygiene.

[32]  R. Cortese,et al.  ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  S. Hoffman,et al.  NF135.C10: A New Plasmodium falciparum Clone for Controlled Human Malaria Infections , 2012, The Journal of infectious diseases.

[34]  R. Coombs,et al.  Laser Cutting Eliminates Nucleic Acid Cross-Contamination in Dried-Blood-Spot Processing , 2012, Journal of Clinical Microbiology.

[35]  R. Sauerwein,et al.  A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. , 2012, Vaccine.

[36]  R. Sauerwein,et al.  Comparison of Clinical and Parasitological Data from Controlled Human Malaria Infection Trials , 2012, PloS one.

[37]  S. Kappe,et al.  Real-time quantitative reverse transcription PCR for monitoring of blood-stage Plasmodium falciparum infections in malaria human challenge trials. , 2012, The American journal of tropical medicine and hygiene.

[38]  E. R. James,et al.  Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity , 2011, Science.

[39]  R. Sauerwein,et al.  Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study , 2011, The Lancet.

[40]  S. Hoffman,et al.  Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial , 2010, PloS one.

[41]  Adrian J F Luty,et al.  Protection against a malaria challenge by sporozoite inoculation. , 2009, The New England journal of medicine.

[42]  V. A. Stewart,et al.  Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A , 2009, PloS one.

[43]  Douglas Chesher,et al.  Evaluating assay precision. , 2008, The Clinical biochemist. Reviews.

[44]  R. Sinden,et al.  Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial , 2008, PloS one.

[45]  T. Bousema,et al.  Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. , 2005, The Netherlands journal of medicine.

[46]  Petra Schneider,et al.  Real-Time Nucleic Acid Sequence-Based Amplification Is More Convenient than Real-Time PCR for Quantification of Plasmodium falciparum , 2005, Journal of Clinical Microbiology.

[47]  G. McConkey,et al.  Plasmodium: the developmentally regulated ribosome. , 1994, Experimental parasitology.

[48]  T. McCutchan,et al.  Developmental regulation of stage-specific ribosome populations in Plasmodium , 1989, Nature.

[49]  D. Herrington,et al.  Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection , 1989, Journal of clinical microbiology.

[50]  T. McCutchan,et al.  Structurally distinct, stage-specific ribosomes occur in Plasmodium. , 1987, Science.

[51]  L. Bruce-Chwatt.  DNA PROBES FOR MALARIA DIAGNOSIS , 1984, The Lancet.

[52]  N. Fairley,et al.  Sidelights on malaria in man obtained by subinoculation experiments. , 1947, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[53]  D. M.,et al.  Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guidelines , 2004 .

[54]  D Payne,et al.  Use and limitations of light microscopy for diagnosing malaria at the primary health care level. , 1988, Bulletin of the World Health Organization.

[55]  T. Burkot,et al.  Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. , 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene.